[1] Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement, 2013; 9, 208-45. doi:  10.1016/j.jalz.2013.02.003
[2] Bilgic B, Hanagasi HA, Emre M. Dementia and behavioral neurology:recent advances. J Neurol, 2012; 259, 1006-10. doi:  10.1007/s00415-012-6460-3
[3] Bateman R. Alzheimer's disease and other dementias:advances in 2014. Lancet Neurol, 2015; 14, 4-6. doi:  10.1016/S1474-4422(14)70301-1
[4] Blennow K, Hampel H, Weiner M, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol, 2010; 6, 131-44. doi:  10.1038/nrneurol.2010.4
[5] Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement, 2011; 7, e13-44. http://www.sciencedirect.com/science/article/pii/S1552526010021849
[6] Kim HJ, Park KW, Kim TE, et al. Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease. J Alzheimers Dis, 2015; 48, 1043-50. doi:  10.3233/JAD-143018
[7] Henriksen K, O'Bryant SE, Hampel H, et al. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement, 2014; 10, 115-31. http://www.ncbi.nlm.nih.gov/pubmed/23850333
[8] Mattsson N, Andreasson U, Zetterberg H, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer Disease. JAMA Neurol, 2017; 74, 557-66. doi:  10.1001/jamaneurol.2016.6117
[9] DeMarshall CA, Nagele EP, Sarkar A, et al. Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimers Dement (Amst), 2016; 3, 51-62. http://www.sciencedirect.com/science/article/pii/S235287291630015X
[10] Peng KA, Masliah E. Lentivirus-Expressed siRNA Vectors Against Alzheimer Disease. Methods Mol Biol, 2010; 614, 215-24. doi:  10.1007/978-1-60761-533-0
[11] Tan L, Yu JT, Hu N, et al. Non-coding RNAs in Alzheimer's disease. Mol Neurobiol, 2013; 47, 382-93. doi:  10.1007/s12035-012-8359-5
[12] Hosseini HM, Fooladi AA, Nourani MR, et al. The Role of Exosomes in Infectious Diseases. Inflamm Allergy Drug Targets, 2013; 12, 29-37. doi:  10.2174/1871528111312010005
[13] Pant S, Hilton H, Burczynski ME. The multifaceted exosome:Biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol, 2012; 83, 1484-94. doi:  10.1016/j.bcp.2011.12.037
[14] Burgos K, Malenica I, Metpally R, et al. Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer's and Parkinson's Diseases Correlate with Disease Status and Features of Pathology. PLoS One, 2014; 9, e94839. doi:  10.1371/journal.pone.0094839
[15] Delay C, Mandemakers W, Hébert SS. MicroRNAs in Alzheimer's disease. Neurobiol Dis, 2012; 46, 285-90. doi:  10.1016/j.nbd.2012.01.003
[16] Cheng L, Doecke JD, Sharples RA, et al. Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry, 2015; 20, 1188-96. doi:  10.1038/mp.2014.127
[17] Fiandaca MS, Kapoqiannis D, Mapstone M, et al. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neutrally-derived blood exosomes:a case-control study. Alzheimers Dement, 2015; 11, 600-7. http://www.sciencedirect.com/science/article/pii/S1552526014024698
[18] Liu CG, Wang JL, Li L, et al. MicroRNA-135a and-200b, potential Biomarkers for Alzheimer's disease, regulate β secretase and amyloid precursor protein. Brain Res, 2014; 1583, 55-64. doi:  10.1016/j.brainres.2014.04.026
[19] Liu CG, Song J, Zhang YQ, et al. MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's disease. Mol Med Rep, 2014; 10, 2395-400. doi:  10.3892/mmr.2014.2484
[20] Liu CG, Wang JL, Li L, et al. MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease. Int J Mol Med, 2014; 34, 160-6. doi:  10.3892/ijmm.2014.1780
[21] Hogervorst E, Bandelow S, Combrinck M, et al. The Validity and Reliability of 6 Sets of Clinical Criteria to Classify Alzheimer's Disease and Vascular Dementia in Cases Confirmed Post-Mortem:Added Value of a Decision Tree Approach. Dement Geriatr Cogn Disord, 2003; 16, 170-80. doi:  10.1159/000071006
[22] Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C, et al. Dementia associated with Parkinson's disease:Applying the Movement Disorder Society Task Force criteria. Parkinsonism Relat Disord, 2011; 17, 621-4. doi:  10.1016/j.parkreldis.2011.05.017
[23] Romàn GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia:diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 1993; 43, 250-60. doi:  10.1212/WNL.43.2.250
[24] Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-ΔΔCT Method. METHODS, 2001; 25, 402-8. doi:  10.1006/meth.2001.1262
[25] Ozarda Y. Reference intervals:current status, recent developments and future considerations. Biochem Med (Zaqreb), 2016; 26, 5-16. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783089/
[26] Tahmasebi H, Higgins V, Fung AWS, et al. Pediatric reference intervals for biochemical markers:gaps and challenges, recent national initiatives and future perspectives. EJIFCC, 2017; 28, 43-63. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387699/
[27] Solberg HE, Lahti A. Detection of outliers in reference distributions:performance of Horn's Algorithm. Clin Chem, 2005; 51, 2326-32. doi:  10.1373/clinchem.2005.058339
[28] Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement, 2014; 10, 844-52. doi:  10.1016/j.jalz.2014.01.001
[29] Lista S, Faltraco F, Prvulovic D, et al. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol, 2013; 101-102, 1-17. http://www.ncbi.nlm.nih.gov/pubmed/22743552
[30] Satoh J. Molecular network of microRNA targets in Alzheimer's disease brains. Exp Neurol, 2012; 235, 436-46. http://www.ncbi.nlm.nih.gov/pubmed/21945006
[31] Xuan Y, Yang H, Zhao L, et al. MicroRNAs in colorectal cancer:Small molecules with big functions. Cancer Lett, 2015; 360, 89-105. doi:  10.1016/j.canlet.2014.11.051
[32] Eulalio A, Schulte L, Vogel J. The mammalian microRNA response to bacterial infections. RNA Biol, 2012; 9, 742-50. doi:  10.4161/rna.20018
[33] van Niel G. Study of exosomes ahed new light on physiology of amyloidogenesis. Cell Mol Neurobiol, 2016; 36, 327-42. doi:  10.1007/s10571-016-0357-0
[34] Kalani A, Tyagi A, Tyagi N. Exosomes:mediators of neurodegeneration, neuroprotection and therapeutics. Mol Neurobiol, 2014; 49, 590-600. http://www.ncbi.nlm.nih.gov/pubmed/23999871?dopt=Abstract
[35] Properzi F, Ferroni E, Poleggi A, et al. The regulation of exosome function in the CNS:implications for neurodegeneration. Swiss Med Wkly, 2015; 145, W14204. http://www.ncbi.nlm.nih.gov/pubmed/26561744
[36] Kalaria RN. Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease. Acta Neuropathol, 2016; 131, 659-85. doi:  10.1007/s00401-016-1571-z
[37] Karbasy K, Ariadne P, Gaglione S, et al. Advances in Pediatric Reference Intervals for Biochemical Markers:Establishment of the Caliper Database in Healthy Children and Adolescents. Swiss Med Wkly, 2015; 34, 23-30. https://www.researchgate.net/publication/273999462_Advances_in_Pediatric_Reference_Intervals_for_Biochemical_Markers_Establishment_of_the_Caliper_Database_in_Healthy_Children_and_AdolescentsNapredak_U_Oblasti_Pedijatrijskih_Referentnih_Intervala_Za_Bi
[38] Fan L, Qi H, Teng J, et al. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer. J Thorac Oncol, 2016; 37, 7777-84. doi:  10.1007/s13277-015-4608-3
[39] Le Calvez-Kelm F, Foll M, Wozniak MB, et al. KRAS mutations in blood circulating cell-free DNA:a pancreatic cancer case-control. Oncotarget, 2016; 7, 78827-40. http://www.ncbi.nlm.nih.gov/pubmed/27705932